key: cord-0799040-b4o9uc1d
authors: Claro, Franklin; Silva, Douglas; Rodriguez, Melissa; Rangel, Rafael; de Waard, Jacobus H.
title: IgG Antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals might need just one vaccine dose.
date: 2021-07-31
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.07.070
sha: 3ccbbbd979ed22aaac97f6ea60d76c38bae881d0
doc_id: 799040
cord_uid: b4o9uc1d

INTRODUCTION: . Serology tests play an important role in assessing the immune system's response to a previous SARS-CoV-2 infection or to vaccination. In Venezuela, before and after receiving the Sputnik V vaccine, we evaluated the IgG antibody response against the nucleocapsid protein (NP) and the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 in a cohort of 86 individuals. METHODS: . Antibody responses against NP and RBD were determined with an ELISA just before, 3 weeks after the first and 6 weeks after the second dose of the vaccine. RESULTS: : Before vaccination, 59 individuals were seronegative and the other 27 were seropositive for SARS-CoV-2 antigens NP and/or RBD. Of the seronegative cohort, 42% did not develop a measurable IgG immune response against RBD after the first vaccine dose but all (100%) had a strong IgG response after two vaccine doses. All seropositive individuals developed a strong IgG antibody response against RBD after the first vaccine dose, with antibody levels approximately 40% higher than the seronegative individuals who had received two doses. Moreover, the previously seropositive subjects showed no significant increase in IgG antibody response against RBD after the second vaccine dose. CONCLUSIONS: : We demonstrated that two dose of the Sputnik V vaccine triggers antibody response in all individuals of this study. The second vaccine dose of Sputnik V has no impact on the IgG response for who were seropositive for SARS-CoV-2 antigens prior to vaccination.

Venezuela has authorized the use of the adenovirus-based vaccine Gam-COVID-Vac (Sputnik V) against COVID-19. Vaccination with Sputnik V relies on a heterologous prime-boost approach using two different adenovirus vectors (Logunov et al. 2021 ) and 3 people are supposed to get two doses, three weeks apart (Jones et al., 2021) . Most other COVID-19 vaccines also require two doses, and current guidelines for COVID-19 vaccines assume that only two doses will give full protection. However, in the light of a shortage in vaccine supplies and the high cost of vaccines, single-dose vaccination is an alternative strategy and a way to expand vaccine supply (Matrajt et al., 2021) .

Several studies have shown that people with previous exposure to SARS-CoV-2 tend to mount powerful immune responses to single vaccine dose, and gain little added benefit from the second vaccine dose. In Sweden, a single dose of the viral vector vaccine Oxford-AstraZeneca vaccine provided protection in previously infected recipients (Havervall et al., 2021) . In the USA, based on serology testing, health care workers with previous COVID-19 infections had higher antibody titer responses after a single dose of the mRNA vaccine of Pfizer-BioNTech or the viral vector vaccine Moderna than those who had not been previously infected (Saadat et al., 2021 , Krammer et al., 2021 , Bradley et al., 2021 . Ebinger et al., 2021 . In Israel, it was found that individuals infected with SARS-CoV-2 pre-vaccination had a strong and persisting IgG response after one dose of the Pfizer-BioNTech vaccine (BNT162b2). Dose 2 in those individuals had no impact on IgG responses Jabal et al., 2021) . In Argentina, individuals with anti-SARS-CoV-2 IgG responses at baseline showed significantly higher responses to the first dose of Sputnik V than people with no prior history of the disease (Chahla et al., 2021) . In Italy, vaccination with BNT162b2 mRNA COVID-19 vaccine showed that in previously infected individuals, neutralizing antibody responses 7 days after the first vaccine dose were not significantly different from those observed in naïve subjects 7 days after the second vaccine dose (Gobby et al., 2021) . In the UK, among participants who had received their 4 first dose of the BNT162b2 mRNA COVID-19 vaccine, the vaccination increased anti-Spike responses at least one order of magnitude greater than what was reported following a conventional prime-boost vaccine strategy in previously uninfected individuals (Manisty et al., 2021) . Furthermore, in India, a single dose of the COVISHIELD vaccine elicited the highest neutralizing antibody response and protective immunity among individuals who had been previously infected (Sasikala et al., 2012) .

Serology testing for SARS-CoV-2 specific antibodies can help us to determine whether vaccination results in the production of SARS-CoV-2 specific antibodies. Serology has been used to follow up on vaccination with several vaccines and in various countries.

Moreover, serology can provide us with data regarding the antibody response acquired 

Participants. We enrolled, randomly, individuals who presented for vaccination (n=149) in a public hospital in Caracas, Venezuela. Before receiving the first dose of the Sputnik V vaccine the participants were interviewed and personal data, underlying illnesses and prior signs/symptoms or proof (RT-PCR positive) of a previous SARS-CoV-2 infection were registered and a blood sample was taken for serology studies. Only vaccine recipients who provided a baseline (pre-vaccine) sample, a sample at the moment of the application of dose 2 and a sample 6 weeks after dose 2 were included in this study (n= 86). Seventy-four were workers at Hospital Vargas, a public hospital in Caracas, and were composed of administrative personnel, doctors, and nurses. Twelve participants came from a research institute (IVIC) in Los Teques, Miranda State, Venezuela.

Vaccination. Individuals received 2 doses of the Sputnik V vaccine, 3 weeks apart. Blood samples were taken at three time points: on day 0 pre-vaccination; day 21 after the first dose; and day 42 after the second dose. All participants (86) of this study were vaccinated with the first vaccine dose during the first week of February 2021.

ELISA and determination of specific IgG antibodies. An in-house ELISA was employed to quantify circulating levels of SARS-CoV-2 anti-nucleocapsid protein (NP) IgG and RBD anti-spike IgG. The antigens utilized in the ELISA were provided by "My BIOSOURCE"

(RBD and NP proteins cat. number MBS8574742 and MBS8574741 respectively) and used 6 for the coating of the ELISA plates (Greiner HB) in a concentration of 1ug/ml. After coating the plates were blocked for 1 hour at 37 ○ C with 300 ul of blocking buffer containing BSA purchased from Sigma (A7906). Serum samples were used in the ELISA at a dilution of 1:100 in blocking buffer and then incubated for 60 min at room temperature (20-25°C). After washing, 100 μl Goat Anti-Human IgG Fc labeled with HRP and diluted at 1:10.000 (ABCAM ab97225) in blocking buffer was added into the wells and the samples were incubated for 60 min at room temperature (20-25°C). Following the second wash cycle, 100 μl TMB substrate (T0440 Sigma-Aldrich) was added into the wells and the samples were incubated for 20 min at room temperature (20-25°C). Last, stop solution was added (0.16M sulfuric acid) into the wells to terminate the reaction. The optical density of each well was determined using a microplate reader set to 450 nm within 10 min.

To allow results to be compared between plates two serum samples (one of a COVID-19 patient, RT-PCR confirmed, who tested positive for IgG antibodies against NP and RBD, and one of a pool of negative controls) were always loaded into two wells each on all ELISA plates. The positive control was selected out of 10 randomly chosen serum samples from convalescent COVID-19, RT-PCR confirmed patients with IgG antibodies for NP and RBD protein, and was the serum sample that was closest to the mean color development (OD) of these 10 serum samples. This positive control serum tended to generate an ELISA absorbance value in the range 0.800-1.00 for the NP and the RBD antigen. The negative control was a pool of 5 human serum samples taken before the COVID-19 pandemic in the year 2019 and randomly chosen from the serum collection of healthy subjects available in our institution. 7 S/P ratio of serum samples. The relative amounts of antibodies in serum samples were calculated by reference to the positive and the negative control. This relationship is expressed as S/P ratio (Sample to Positive Ratio) and was calculated using the following formula: ((OD sample-OD negative control)/(OD positive control -OD negative control))x100%. An S/P value of 40% or more was considered positive and corresponded with the mean of the 5 negative sera and two standard deviations (SD). Sensitivity and specificity of the ELISA was determined with 40 RT-PCR positive serum samples, taken 4-6 weeks after the initial diagnosis and 30 negative control samples of healthy individuals and collected before the COVID-19 pandemic. Sensitivity and specificity for the RD and NP antigens were respectively 97.5/100% and 96.7/100% Survey. With simple and direct questions, participants were asked for the following information: sex, age, whether they had experienced any of the most common symptoms of COVID-19 (fever, persistent dry cough, fatigue and a loss of smell and/or taste) over the last year, results of previous COVID tests, use of medicines (particularly the use of immunosuppressants), and underlying illnesses. 

Participants of the study. Of the 146 individuals who initially collaborated only 86 were eligible for this study as the others did not provide a sample after the first or second vaccine dose. The ages of the participants ranged from 21 to 76 with the mean age of 41±13.2 and 49 (57%) were women. 30% of individuals reported at least one chronic condition;

hypertension (17 individuals), diabetes (4) and asthma (5). (See Figure 1 and Table 1 ). For the seronegative cohort no statistically significant difference was observed between antibody responses elicited in males and females or individuals with an underlying disease. However, although not significant different, a lower IgG response was associated with older age and not with underlying illnesses or sex. The mean for the IgG response in the older age group (60 years or more n=8) was 36, SD=42 compared with 87, SD=98 in the age group of 21-59 years.

IgG antibodies after the second vaccine dose. Six weeks after receiving the second dose, all participants were invited back to be interviewed and for blood samples to be taken. All participants of the seronegative cohort now had measurable IgG antibody responses (mean S/P value=244, SD=73) that were approximately 2 times higher than after the first vaccine dose. The IgG antibody responses of the seropositive cohort remained high, without a significant change after the second vaccine dose (S/P value 337, SD=12) and were on average 40% higher than the seronegative cohort. Equally, the second dose did not increase the IgG responses in the seropositive cohort (See Figure 1 and Table 1 ). Again no statistically significant difference was observed between antibody responses elicited in males and females or individuals with an underlying disease. Similarly, when the participants of the seronegative cohort were grouped according to age (age ranges of 21-49 (n=20); 50-59 (n=25); and 60-76 (n=8)), no statistical difference was found between mean antibody responses elicited by each age group. However, again the IgG response in the older age group was a 30% lower in comparison with the other age groups (S/P value 188, Table 1 .

The aim of this study was to evaluate IgG responses to the Sputnik V vaccine among vaccinated individuals in Venezuela in accordance with their serostatus for SARS-CoV-2 antigens before vaccination. just before or shortly after the second dose. The infection was not confirmed with a RT-PCR however, the four individuals reported fever (4), dry cough (3), headache (2) and tiredness (4) as the most common symptoms and 3 out of 4 lost their smell. Smell loss is a good predictor for COVID-19 and can be attested a high specificity (97%) and a sensitivity of 65%. (Haehner et al. 2021 , Gerkinet al 2021 , Said et al 2021 . Moreover, a rapid olfactory test as a potential screening tool for COVID-19 has been reported (Said et al. 2021 ). These four individuals also developed a strong IgG response against the NP antigen (see figure 1 and table 1) . We consequently consider these four cases as breakthrough infections and it is therefore vital not to assume that individuals after their first dose are fully protected. No breakthrough infections were registered in the seropositive cohort.

We showed that all individuals seropositive for SARS-CoV-2 antibodies, displayed RBD- 

Our study measured circulating antibody levels and interpreting the significance of differences in IgG levels for protection is difficult. No levels of "neutralizing" antibodies or virus neutralization assay was performed thus we would not presume to interpret our data with respect to vaccine efficacy. Further studies are needed to assess how antibody levels relate to vaccine protection against COVID-19.

Our study demonstrates no benefits for the vaccine induced IgG response in receiving a second dose among all the individuals who were seropositive prior to vaccination.

However, the numbers in our study (and also most other studies mentioned in the introduction ) are small and the results need to be confirmed in larger and more diverse populations, with more power regarding sample size and across demographic and clinical sub-groups that are known to exhibit variations in antibody response following vaccination.

Underlying illness and sex had no significant impact on the IgG response in our study however, the older age group, although not significant, showed a lower IgG response in comparison with younger age groups.

RT-PCR testing was scarcely practiced in our study population and we had to rely on signs, symptoms (especially a loss of smell), and elevated antibody levels against RBD or NP to classify our patients into 2 groups: seronegative and possibly never infected and seropositive or possibly previously infected individuals. However, we do not exclude that some of the high IgG responders after one vaccine dose in seronegative cohort got previously infected but lost their antibody response over time and that the first vaccine dose acted as a booster.

We tested for vaccine induced antibodies 6 weeks after the second vaccine dose. It remains to be seen how long vaccine-induced antibody responses among seropositive, naturally infected individuals will last compared to non-infected seronegative individuals and this requires long-term follow-up.

Distinct SARS-CoV-2 Antibody Responses Elicited by Natural Infection and mRNA Vaccination

Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine

Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose MedRxiv doi

neutralising antibody responses and duration of immunity: a longitudinal study

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Recent smell loss is the best predictor of COVID-19 among individuals with recent respiratory symptoms

Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection

Predictive Value of Sudden Olfactory Loss in the Diagnosis of COVID-19

Antibody Responses after a Single Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-CoV-2. medRxiv preprint

Implications for vaccination policy

Sputnik V COVID-19 vaccine candidate appears safe and effective

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Optimizing vaccine allocation for COVID-19 vaccines: critical role of single-dose vaccination

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Binding and Neutralization Antibody Responses After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

A Rapid Olfactory Test as a Potential Screening Tool for COVID-19

Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals

References.

FECA, DS, and JHdW designed the study, developed the ELISA assay and, with the participation of RR, recruited the participants for this study. FC, DS, and MX performed the laboratory experiments. The authors had full access to all data, searched for relevant literature, participated in writing the first draft, and read and approved the final manuscript.Both FECA and DS can be considered as primary authors and contributed equally. All authors declare no competing interests.

This study was funded by the "Fondo Nacional de Ciencia y Tecnología" (FONACIT).JhdW is supported by the Universidad de Las Americas, in Quito, Ecuador. The funders had no role in study design, data collection, or the decision to publish this article.

The study was approved by the Institutional Ethics Committee of Hospital Vargas de Caracas, Caracas, Venezuela

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: